Morris Matthew Shawn sold $3.1M of PRVA
Morris Matthew Shawn sold 112,759 shares of Privia Health Group, Inc. (PRVA) at an average of $27.29 ($27.24–$27.33, $3.08M total) across 2 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale size, price range, and post-transaction holdings by a director under a 10b5-1 plan; it informs sentiment but not fundamentals.
Market read
Traders may monitor PRVA for follow-on insider activity, but the 10b5-1 framing reduces the likelihood of a strong fundamental read-through.
What to watch
The article does not state whether there were concurrent buys, option exercises, or broader insider activity; without that context, the signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Privia Health Group, Inc. (PRVA).
Ticker impact
Privia Health Group director Morris Matthew Shawn sold 112,759 shares in open-market trades totaling about $3.08M under a 10b5-1 plan.
Likely limited immediate price impact; any effect would be sentiment-driven and modest unless accompanied by other news.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the article provides only the sale details (no new fundamentals, guidance, or legal/operational catalyst).
Market effects
Minimal—this is company-specific insider activity with no sector-wide regulatory or operational signal.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated or sizable sales can be interpreted by some traders as management de-risking ahead of uncertainty, potentially pressuring sentiment.
Key entities
- issuerPrivia Health Group, Inc.
Subject of the Form 4 insider transaction disclosure (PRVA).
- insiderMorris Matthew Shawn
Director who sold 112,759 shares in two open-market trades under a 10b5-1 plan.
